ACB · Aurora Cannabis Inc.

The grant of Plant Breeders’ Rights in Canada represents a tangible milestone in Aurora’s long-term strategy to build a defensible, science-based platform in medical cannabis. Unlike transactional or financial disclosures, this event signals progress in proprietary asset development: the protected cultivars were selected for their agronomic performance and consistency—key attributes for medical-grade supply—and are already deployed across multiple regulated international markets. The CFIA certification provides Aurora with enforceable exclusivity over propagation and commercialization, reducing generic competition risk for these specific genetics and supporting premium pricing potential. While not revenue-generating in isolation, the grant validates Aurora’s R&D infrastructure—including its GMP-certified facilities and breeding pipeline—and strengthens its ability to deliver reproducible clinical outcomes, a critical factor for healthcare providers and payors in markets like Germany and the UK. Management explicitly ties the rights to 'consistency, performance and reliability for medical cannabis patients around the world,' underscoring their role in fulfilling Aurora’s medical-first positioning. Though no financial terms, timelines, or revenue impact are disclosed, the inclusion of forward-looking statements about enhanced global competitive position indicates strategic weight beyond routine IP maintenance.